INVIVYD INC(NASDAQ:IVVD) stock News

IVVD Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Zacks Investment Research - Mentions: ALEC

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

5 days ago - By: Zacks Investment Research - Mentions: RPRX

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

19 days ago - By: Invivyd

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

19 days ago - By: Invivyd

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

3 months ago - By: Benzinga

What to Expect from Invivyd's Earnings

21 days ago - By: Invivyd

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

21 days ago - By: Invivyd

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

a month ago - By: Invivyd

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

a month ago - By: Invivyd

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

2 months ago - By: Invivyd

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

2 months ago - By: Invivyd

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

2 months ago - By: Yahoo Finance - Mentions: NPCE ENPH HOWL KROS ...

H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating

2 months ago - By: Yahoo Finance - Mentions: NPCE HOWL THC KROS ...

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall

3 months ago - By: Benzinga - Mentions: AVR TNXP RAPT WORX ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

3 months ago - By: Invivyd

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2

3 months ago - By: Invivyd

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2

3 months ago - By: Invivyd

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

3 months ago - By: Invivyd

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

3 months ago - By: Invivyd

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

3 months ago - By: Invivyd

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

3 months ago - By: Zacks Investment Research - Mentions: CVAC

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

3 months ago - By: Invivyd

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

3 months ago - By: Invivyd

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

3 months ago - By: Invivyd

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

3 months ago - By: Invivyd

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

3 months ago - By: Invivyd

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

3 months ago - By: Invivyd

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

3 months ago - By: Invivyd

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

3 months ago - By: Invivyd

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

3 months ago - By: Invivyd

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

3 months ago - By: Invivyd

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

4 months ago - By: Yahoo Finance - Mentions: CFG

INVIVYD INC (IVVD) Stock News

IVVD Latest News, Press Relases and Analysis

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome

What to Expect from Invivyd's Earnings

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall

12 Health Care Stocks Moving In Tuesday's Intraday Session

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

What's Going On With Invivyd Stock On Monday?